Lexicon Pharmaceuticals
  • Home
  • Contact Us
  • Site Map
  • About Us
    • About Us Home
    • Management Team
    • Board of Directors
    • Development Team
    • Locations
    • Contact Us
    • History
  • Pipeline
    • Drug Pipeline Home
    • Our Goal
    • Therapeutic Areas
    • Drug Development Team
    • Clinical Trials
    • Publications
  • Discovery
    • Discovery Home
    • Discovery Process
    • Technology
    • Genome5000
    • Medicinal Chemistry
    • Biotherapeutics
    • Patents
    • Academic Access
    • Technology Licensing
  • Alliances
    • Alliances Home
    • Current Alliances
    • Technology Licensing
  • Careers
    • Careers Home
    • Opportunities
    • Our Culture
    • Benefits
    • Community Involvement
    • The Woodlands
    • Princeton
    • Awards and Recognition
  • News
    • News Home
    • Media Inquiries
  • Investors
    • Investors Home
    • Media
    • Events
    • Stock Quote
    • SEC Filings
    • Annual Reports
    • Corporate Governance
    • Request Information
Lexicon Banner
  • News Home
  • Media Inquiries
Subscribe
Press Releases
Filter     Display # 
10/15/2007 Lexicon Reports Initial Clinical Trial Results for LX1031, An Investigational New Drug For Irritable Bowel Syndrome
10/04/2007 Lexicon Pharmaceuticals to Present at BIO InvestorForum
09/27/2007 Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
09/24/2007 Lexicon Appoints Judith Swain, M.D. to Board of Directors
09/20/2007 Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
08/23/2007 Lexicon Pharmaceuticals Announces Stockholder Approval of Invus Investment of Up to $550 Million
08/21/2007 Lexicon Presents Class Of Compounds Modulating TPH1, The Target For Its LX1031 Investigational Drug For Irritable Bowel Syndrome
08/12/2007 Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
07/31/2007 Lexicon Pharmaceuticals Reports 2007 Second Quarter Financial Results
07/30/2007 Lexicon Drug Candidate For Cognitive Disorders Successfully Completes Phase 1 Clinical Trial
 
«StartPrev12345678910NextEnd»
Page 4 of 32
  • About Us
  • Pipeline
  • Discovery
  • Alliances
  • Careers
  • Investors
  • Terms Of Use

Copyright © 2008, Lexicon Pharmaceuticals, Inc. All rights reserved.